News >

Ruxolitinib Plus Capecitabine Improves Survival in Pancreatic Cancer

Ben Leach
Published: Wednesday, Aug 21, 2013

Dr. Paul A. Friedman

Paul A. Friedman, MD

Ruxolitinib (Jakafi) significantly improved the survival rate of a subgroup of patients with recurrent or treatment-refractory pancreatic cancer—those who were expected to benefit from the drug the most when given in combination with the chemotherapy agent capecitabine—compared with patients in the same population who received capecitabine alone, according to top-line results of a phase II proof-of-concept study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication